V. Tochilov

PSYCHOEMOTIONAL STATUS FEATURES IN PATIENTS WITH THYROID GLAND PATHOLOGY

S. Kotova, Минздрава России, J. V. Sinitsina, 2014 .

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

S. Mosolov, D. Schoepp, Lu Zhang, 2007, Nature Medicine.

mGlu2/3 Agonists – a New Approach to the Treatment of Schizophrenia: Results of a Randomized Double-Blind Trial

S. Mosolov, F. Martényi, L. Bardenstein, 2011, Neuroscience and Behavioral Physiology.

[The use of mGlu2/3 receptors as a new approach to treat schizophrenia: results of a randomized double-blind trial].

S. Mosolov, F. Martényi, A. Avedisova, 2010, Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova.

Olanzapine versus divalproex versus placebo in the treatment of mild to moderate mania: a randomized, 12-week, double-blind study.

J. Amsterdam, M. Tohen, G. Goodwin, 2008, The Journal of clinical psychiatry.

The effect of stereotactic cingulocapsulotomy in obsessive compulsive disorders

O. N. Kushnir, A. D. Anichkov, I. Plotnikova, 2008 .

Corrigenda: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

S. Mosolov, D. Schoepp, Lu Zhang, 2007, Nature Medicine.